Joshi J. Alumkal, M.D.
Dr. Alumkal's research interest is cancer epigenetics, the study of heritable and potentially reversible changes in gene expression in cancer. His laboratory studies key chromatin modifying enzymes in cancer with an eye towards: 1) elucidating their function and role in transformation and disease progression and 2) targeting them with pharmacological agents in order to improve our ability to prevent and treat men with prostate cancer. Finally, his laboratory also focuses on the identification of biomarkers associated with prostate cancer development or aggressiveness.
"Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation,"
"Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer study,"
"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase i/ii study,"
"Targeted MET inhibition in castration-resistant prostate cancer: A randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone,"
"Targeted therapy in prostate cancer: is there hope beyond the androgen receptor?,"